These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 28482292)

  • 21. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The significance of GlgE as a new target for tuberculosis.
    Kalscheuer R; Jacobs WR
    Drug News Perspect; 2010 Dec; 23(10):619-24. PubMed ID: 21180647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New tuberculosis drugs on the horizon.
    Cole ST; Riccardi G
    Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach.
    Biava M; Porretta GC; Poce G; Battilocchio C; Alfonso S; de Logu A; Manetti F; Botta M
    ChemMedChem; 2011 Apr; 6(4):593-9. PubMed ID: 21341373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycobacterium tuberculosis... Can we beat it? Report from a Euroscicon conference 2013.
    Maitra A; Bhakta S
    Virulence; 2013 Aug; 4(6):499-503. PubMed ID: 23863609
    [No Abstract]   [Full Text] [Related]  

  • 26. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
    Sharma A; Khuller GK; Sharma S
    Expert Opin Ther Targets; 2009 Jul; 13(7):753-65. PubMed ID: 19530983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and validation of novel drug targets in Mycobacterium tuberculosis.
    Singh V; Mizrahi V
    Drug Discov Today; 2017 Mar; 22(3):503-509. PubMed ID: 27649943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.
    Nikonenko BV; Protopopova M; Samala R; Einck L; Nacy CA
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1563-5. PubMed ID: 17242141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospects for new antitubercular drugs.
    Duncan K; Barry CE
    Curr Opin Microbiol; 2004 Oct; 7(5):460-5. PubMed ID: 15451500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Progress in role of novel anti-tuberculosis drug targets and their inhibitors].
    Ji L; Xie J
    Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1326-1337. PubMed ID: 30152218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New frontiers in the therapy of tuberculosis: fighting with the global menace.
    Chhabria M; Jani M; Patel S
    Mini Rev Med Chem; 2009 Apr; 9(4):401-30. PubMed ID: 19356120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposed drug candidates for antituberculosis therapy.
    An Q; Li C; Chen Y; Deng Y; Yang T; Luo Y
    Eur J Med Chem; 2020 Apr; 192():112175. PubMed ID: 32126450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anti-tuberculosis agents under development and the challenges ahead.
    Kumar D; Negi B; Rawat DS
    Future Med Chem; 2015; 7(15):1981-2003. PubMed ID: 26505682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycobacterium tuberculosis: drug resistance and future perspectives.
    Riccardi G; Pasca MR; Buroni S
    Future Microbiol; 2009 Jun; 4(5):597-614. PubMed ID: 19492969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Worldwide emergence of extensively drug-resistant tuberculosis.
    Shah NS; Wright A; Bai GH; Barrera L; Boulahbal F; Martín-Casabona N; Drobniewski F; Gilpin C; Havelková M; Lepe R; Lumb R; Metchock B; Portaels F; Rodrigues MF; Rüsch-Gerdes S; Van Deun A; Vincent V; Laserson K; Wells C; Cegielski JP
    Emerg Infect Dis; 2007 Mar; 13(3):380-7. PubMed ID: 17552090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them.
    Evangelopoulos D; da Fonseca JD; Waddell SJ
    Int J Infect Dis; 2015 Mar; 32():76-80. PubMed ID: 25809760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing TB in the 21st century: existing and novel drug therapies.
    Guy ES; Mallampalli A
    Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging drugs and drug targets against tuberculosis.
    Lambert N; Abdalla AE; Duan X; Xie J
    J Drug Target; 2017 Apr; 25(4):296-306. PubMed ID: 27822967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.